901 Immunohistochemical Profile of Molecularly Verified Clear Cell Renal Cell Carcinomas. Read more about 901 Immunohistochemical Profile of Molecularly Verified Clear Cell Renal Cell Carcinomas.
891 DNA Damage Repair Mutations in Renal Cell Carcinomas. Read more about 891 DNA Damage Repair Mutations in Renal Cell Carcinomas.
823 Molecular, Morphologic, and Immunohistochemical Characteristics of Tumors in Patients on Active Surveillance for Low Grade Prostatic Adenocarcinoma Who Developed Metastasis. Read more about 823 Molecular, Morphologic, and Immunohistochemical Characteristics of Tumors in Patients on Active Surveillance for Low Grade Prostatic Adenocarcinoma Who Developed Metastasis.
822 Correlation of the Degree of Pleomorphism and Lymphocytic Infiltration with Tumor Mutational Burden in High-Grade Urothelial Carcinoma. Read more about 822 Correlation of the Degree of Pleomorphism and Lymphocytic Infiltration with Tumor Mutational Burden in High-Grade Urothelial Carcinoma.
811 Correlation of Unfavorable, Borderline, and Favorable Histology at Radical Prostatectomy with Decipher Scores and Freedom from Biochemical Recurrence. Read more about 811 Correlation of Unfavorable, Borderline, and Favorable Histology at Radical Prostatectomy with Decipher Scores and Freedom from Biochemical Recurrence.
806 Immunohistochemical Examination of CA-125 in Invasive Urothelial Carcinoma Histologic Variants. Read more about 806 Immunohistochemical Examination of CA-125 in Invasive Urothelial Carcinoma Histologic Variants.
786 Clinical and Morphological Characterization of RAS/RAF/MAPK-Mutated Prostatic Adenocarcinoma. Read more about 786 Clinical and Morphological Characterization of RAS/RAF/MAPK-Mutated Prostatic Adenocarcinoma.
785 Evaluation of Atypical Intraductal Proliferation in Patients with Grade Group 1-2 or No Invasive Cancer on Prostate Biopsies including Decipher, PTEN and Subsequent Biopsy/Radical Prostatectomy Follow-up. Read more about 785 Evaluation of Atypical Intraductal Proliferation in Patients with Grade Group 1-2 or No Invasive Cancer on Prostate Biopsies including Decipher, PTEN and Subsequent Biopsy/Radical Prostatectomy Follow-up.
384 The Utility of Next-Generation Sequencing in Metastatic Prostate Cancer Fine-Needle Aspiration Biopsies. Read more about 384 The Utility of Next-Generation Sequencing in Metastatic Prostate Cancer Fine-Needle Aspiration Biopsies.
410 Fine Needle Aspiration Biopsy of Breast Specimens Effectively Harvests Cells for Patient-Derived Organoids Modeling Breast Ductal Carcinoma In Situ. Read more about 410 Fine Needle Aspiration Biopsy of Breast Specimens Effectively Harvests Cells for Patient-Derived Organoids Modeling Breast Ductal Carcinoma In Situ.
